Just two days ago the director of the Gamaleya Research Institute of Epidemiology and Microbiology Alexander Gintsburg reported excellent trial results in mice: while unvaccinated mice with melanoma died between the 19th and 22nd days of the trial, their vaccinated counterparts remained alive.

The critical point is that this vaccine works with any type of cancer – it will be customized for individual patients. The virus cells in the groundbreaking vaccine will contain very high concentrations of target antigen replicated from the antigen produced by the patient’s cancerous cells. When delivered to the body, the vaccine will teach the immune system how to distinguish between the normal and cancerous cells, thus helping to selectively kill the latter.

This is another exciting development from the Gamaleya Research Institute. Congratulations are in order.